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Abstract 
 
Epidermal growth factor receptor (EGFR) gene amplification as well as activating mutations 
are common findings in glioblastomas. EGFR is on top of a down-stream signalling cascade 
which regulates important characteristics of glioblastoma cells including cellular proliferation, 
migration and survival. Targeting EGFR has therefore been regarded a promising therapeutic 
strategy in glioblastoma for decades. However, although various pharmacological inhibitors 
and anti-EGFR antibodies are available, the anti-glioma activity of these agents has been 
largely limited to preclinical models whereas their administration to glioblastoma patients was 
characterized by lack of clinical benefit. Comprehensive efforts have been made within the 
last years to understand the underlying mechanisms which confer resistance to EGFR 
inhibition in glioma cells. The absence of well-known mutations which predict response to 
EGFR tyrosine kinase inhibitors in gliomas as well as the presence of redundant and 
alternative compensatory pathways are among the most important escape mechanisms that 
prevent potent anti-glioma effects of EGFR-targeting drugs. Accordingly, an increasing 
number of in vitro and in vivo studies aimed at overcoming this resistance by combinatorial 
approaches using anti-EGFR treatment together with one or more additional drugs. Novel 
insights into the molecular mechanisms mediating resistance to anti-EGFR treatment and 
promising combinatorial approaches may help to better define a future role for EGFR 
inhibition in the treatment of glioblastoma.
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Background 
 
Gliomas are the most common primary brain tumors in adults. They are classified according 
to the World Health Organisation (WHO) into grades I-IV with glioblastoma being the most 
malignant subtype. Despite all efforts, median survival in glioblastoma patients is restricted 
to approximately 16 months in clinical trial populations 1. Various therapeutic strategies have 
been explored within the last years in order to improve the prognosis of glioblastoma 
patients. Several of these novel strategies aim at targeting specific molecules or signalling 
pathways that are deregulated in glioma cells. Among the genetic aberration associated with 
gliomas, amplification of the epidermal growth factor receptor (EGFR, also named HER1 or 
ERBB1) is a frequent finding which has been described in approximately 40-50% of all 
glioblastomas 2. Besides EGFR, the family of HER receptor tyrosine kinases comprises 
ERBB2 (more frequently known as HER2/neu), ERBB3, and ERBB4. EGFR binds several 
ligands including epidermal growth factor (EGF), transforming growth factor (TGF)-α, 
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin, epigen and 
epiregulin 3. Engagement of EGFR results in the activation of a cytoplasmatic tyrosine kinase 
(TK) domain and subsequent intracellular downstream signalling involving, among others, 
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 
pathways 2. Thus, EGFR signalling affects various cellular processes including proliferation, 
survival and metabolism. Amplification of EGFR is frequently associated with the 
occurrence of a mutant form of EGFR called EGFR variant III (EGFRvIII, also known as 
ΔEGFR). EGFRvIII is found in approximately 25-30% of all glioblastomas. However, there 
are various other mutations in EGFR, some of which predict a response to pharmacological 
inhibitors (see below). Because of its role as a central regulator of various biological 
processes in glioma cells as well as its potential contribution to resistance to apoptotic stimuli 
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and alkylating chemotherapy with temozolomide 4,5, EGFR has attracted much attention as a 
therapeutic target. 
 
Resistance to pharmacological EGFR inhibitors and antibodies targeting EGFR 
 
As outlined above, EGFR has been regarded as a promising point of attack for therapeutic 
interventions against malignant gliomas. However, most approaches used so far have shown 
disappointing results in the clinic with virtually no benefit for populations of unselected 
patients. Thus, a major research focus within the last years has been the deciphering of the 
molecular mechanisms underlying the resistance of glioma cells to EGFR inhibition. The 
following section describes EGFR-targeted therapies as well as molecular alterations that may 
confer resistance to EGFR inhibition. 
 
Pharmacological EGFR inhibitors 
Pharmacological inhibitors, mostly small molecule tyrosine kinase inhibitors (TKI), targeting 
EGFR have been extensively tested in preclinical glioma models. Similar to other tumor 
entities such as lung carcinomas, where these drugs are well established in clinical practice, 
most investigators used erlotinib or gefitinib to interfere with EGFR signalling. The EGFR-
blocking activity of erlotinib and gefitinib largely depends on the presence of mutations in 
exons 19 and 21 of the TK domain. These mutations are commonly found in lung cancer and 
other tumor entities and led to the approval of several EGFR inhibitors. However, these 
“sensitizing” mutations are virtually absent in glioblastomas, which may partially explain the 
lacking activity of standard TKI in this disease 6-9.  
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Antibodies against EGFR 
Antibodies directed against EGFR with cetuximab, nimotuzumab and panitumumab as the 
most prominent candidates were also investigated for their anti-glioma activity in vitro and in 
vivo. Antibodies may exert their effect by preventing the binding of EGFR ligands to the 
receptor. Furthermore, antibody binding may result in receptor internalization and 
degradation 10. Although antibodies to EGFR have been approved for other cancer types, e.g., 
cetuximab for the treatment of KRAS wild type colon cancer, their use against intracranial 
neoplasms such as glioblastoma represents a challenge due to the presence of the blood-brain 
barrier which may preclude the penetration of the antibody to all parts of the tumor. 
However, small molecule EGFR inhibitors such as erlotinib and gefitinib did also not 
markedly inhibit EGFR phosphorylation in vivo 11. Accordingly, the blood-brain barrier may 
represent an important “resistance factor” that limits the activity of EGFR-targeting drugs in 
the brain.  
 
General mechanisms of resistance to EGFR-targeted therapies 
The escape of glioma cells from EGFR-targeted therapy is caused by several characteristics 
of these cells and particularly by the existence of multiple overlapping and alternative 
compensatory signalling pathways which allow for a loss of EGFR function without 
detrimental effects on the cells 12,13. One common finding in glioma cells, that is, loss of 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) has been identified as a 
resistance factor to drugs directed against EGFR. PTEN loss promotes resistance to EGFR 
presumably by dissociating EGFR inhibition from down-stream inhibition of the PI3K 
pathway 7,14. Inhibition of mTOR restores the sensitivity of PTEN-deficient gliomas to EGFR 
inhibitors 7,15,16. Since 40% to 50% of glioblastomas lack PTEN expression, these findings 
were the rationale for the combined used of EGFR and mTOR inhibitors in human patients 
(see below). Furthermore, it became obvious that even in glioblastoma specimens with wild-
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type PTEN expression, resistance to EGFR inhibitors may occur as a result of 
phosphorylation of PTEN at the conserved tyrosine residue Y240 17. 
One of the most comprehensive strategies aiming at identifying molecules and pathways that 
mediate resistance to EGFR inhibition has been the use of genome-wide small hairpin 
(sh)RNA screens. The application of such an approach revealed the dopamine receptor D2 
(DRD2) signalling pathway as a novel therapeutic target. Combined inhibition of DRD2 
signalling and EGFR inhibition resulted in synergistic anti-glioma activity in in vitro and in 
vivo models 18. 
Glioma cells can be characterized by intrinsic resistance to EGFR inhibitors or acquired 
mechanisms that allow them to escape from EGFR-targeted treatment. Acquired resistance to 
EGFR inhibition in EGFR-mutant glioma cells is conferred by an induction of platelet-
derived growth factor receptor (PDGFR)-β expression. Consequently, the combined targeting 
of EGFR and PDGFR-β resulted in more potent anti-tumor activity in preclinical glioma 
models than either treatment alone 19. Furthermore, expression of the promyelocytic leukemia 
(PML) gene in glioma cells prevents the induction of cell death in response to EGFR 
inhibition 20. Abrogation of PML expression by siRNA-mediated gene silencing or 
administration of the PML inhibitor arsenic trioxide restored the susceptibility of 
experimental gliomas in vivo to EGFR inhibition. 
The fact that not all tumor cells share the same molecular make-up may also contribute to 
resistance to EGFR inhibition. In this regard, a population of cells within gliomas that exhibit 
stem cell-like properties has been described within the last years. These cells, also known as 
glioma-initiating cells (GIC), have been proposed as a major factor for the ultimately lethal 
course of the disease due to their contribution to the resistance of gliomas to various 
treatments. Preclinical data indicate that the resistance of GIC to EGFR inhibition is partially 
due to focal adhesion kinase (FAK)-mediated integrin β1 signalling 21. A similar study 
revealed that only co-treatment consisting of erlotinib and the hedgehog pathway inhibitor 
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cyclopamine had an effect on sphere initiation in glioblastoma stem-cell cultures 22. These 
reports demonstrate that anti-EGFR strategies hold promise in targeting the stem cell 
population within glioblastomas. However, they also suggest that EGFR inhibition alone is 
insufficient and needs to be combined with the therapeutic targeting of at least one additional 
pathway. Further studies are required to define which combination may work best and which 
of the available combinations ultimately succeeds in human patients.  
 
 
Clinical trials and combined treatment approaches in patients with malignant gliomas 
 
Treatment of glioma patients with pharmacological EGFR inhibitors or blocking antibodies as 
single treatment has been largely futile. Several trials, using anti-EGFR approaches for 
gliomas with different WHO grades in the settings of newly diagnosed or recurrent tumors, 
have failed to show signs of activity. However, as outlined above, extensive preclinical work 
demonstrated that the disruption of converging signalling pathways may help to overcome 
resistance to EGFR inhibitors. Based on the increasing awareness that combinatorial targeting 
of EGFR and one or more additional molecule(s) may exert more robust anti-tumor activity, 
various trials were initiated using combinations of EGFR-targeting agents and additional 
drugs.  
 
Clinical administration of TKI 
Several preclinical reports suggest a sensitizing effect of EGFR inhibition to irradiation 23. 
Accordingly, clinical trials were designed to explore the combination of radiation therapy 
with EGFR inhibitors in patients with newly diagnosed glioblastoma. However, such trials 
failed to show benefit from addition of gefitinib or erlotinib to radiation therapy compared to 
historical controls. Notably, these trials completed enrolment before the introduction of 
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temozolomide to the standard of care for glioblastoma patients 24,25. Addition of erlotinib to 
temozolomide-based chemoradiation in patients with newly diagnosed glioblastoma resulted 
in prolonged overall survival compared to historical controls 26 but confirmation of this 
finding in a randomized trial is lacking and seems not to be further pursued. A phase I/II study 
explored the combination of the EGFR inhibitor lapatinib and the multikinase inhibitor 
pazopanib in patients with recurrent malignant glioma patients. Here, patients were stratified 
into 2 groups with either intact PTEN or EGFRvIII expression or without PTEN and 
EGFRvIII expression. However, the overall limited activity of this regimen did not differ 
among patients stratified by tumor EGFRvIII or PTEN status. A pharmacokinetic analysis 
demonstrated that only subtherapeutic levels of lapatinib were reached which may have 
precluded sufficient inhibition of EGFR signalling 27. The combined administration of the 
mechanistic target of rapamycin (mTOR) inhibitor, everolimus, and gefitinib did not achieve 
durable responses in patients with recurrent glioblastoma 28. Similarly, a phase I/II trial 
exploring the combination of erlotinib with the mTOR inhibitor temsirolimus in patients with 
recurrent malignant glioma failed to prove relevant anti-tumor activity. However, dose-
limiting toxicity involving rash and mucositis was common 29. Low tumor levels of both 
drugs and the failure to prove target inhibition in the posttreatment tissue of several patients 
may partially explain the futility of this regimen. Compared to the “first-generation” EGFR 
inhibitors, second-generation, irreversible, TKI may exert more potent anti-glioma activity. 
However, one of these novel drugs, afatinib, did not show any signs of activity when used as 
single agent and did not improve the outcome of patients with recurrent glioblastoma in 
combination with temozolomide, likely because of negligible blood brain barrier penetration 
30. Other compounds such as dacomitinib (PF-00299804) are currently being tested in clinical 
trials enrolling patients with recurrent glioblastoma (NCT01520870 and NCT01112527).   
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Anti-EGFR antibodies 
The anti-EGFR antibody nimotuzumab was assessed in several clinical trials in patients with 
high-grade gliomas either alone or in combination with other treatment modalities and 
demonstrated only modest or no signs of activity 31,32. The lacking benefit of this regimen 
may be explained by the recent finding that treatment of glioma cells with an anti-EGFR 
antibody enhances DNA repair and thereby abrogates the effectiveness of DNA-damaging 
agents 33. Accordingly, the development of more elaborated strategies that combine irradiation 
and/or alkylating chemotherapy with anti-EGFR strategies is required. Novel anti-EGFR 
antibodies such as mAb806 target EGFRvIII and a subset of the overexpressed wild type 
EGFR but do not interact with wild-type EGFR expressed by normal cells. The administration 
of mAb806 has shown promising results in preclinical glioma models 34,35. However, data on 
its putative clinical activity are still lacking. Further strategies include the administration of 
antibody-drug conjugates (ADC) which comprise of an anti-EGFR antibody conjugated to 
potent cytotoxic drugs. ABT-414 is an ADC which mainly interacts with tumor cells 
expressing wild-type amplified EGFR or EGFRvIII. The activity of ABT-414 against 
glioblastoma is currently tested in clinical trials 36. In a similar approach, administration of a 
125I-labeled anti-EGFR antibody (125I-MAb 425) in combination with radiation therapy did not 
result in better outcome compared to irradiation alone in patients with anaplastic glioma or 
glioblastoma 37.  
 
Preclinical developments 
Novel drug conjugates such as DAB389EGF, a fusion protein composed of diphtheria toxin 
linked to EGF have shown activity in experimental glioma models 38. Further approaches that 
have not yet reached the clinic include EGFR gene silencing by RNA interference or 
ribozyme-mediated cleavage of EGFR mRNA molecules 39,40. It needs to be awaited whether 
these techniques may become available for clinical testing in the future.  
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Resistance to therapeutic approaches specifically targeting EGFRvIII 
 
EGFRvIII has been described as a mediator of glioma cell resistance to chemotherapeutic 
drugs in vitro through up-regulation of the anti-apoptotic protein Bcl-XL 41. However, the 
clinical impact of EGFRvIII expression on progression-free and overall survival has remained 
controversial. A report assessing tumor samples from 73 patients revealed an association of 
EGFRvIII expression with prolonged overall survival 42. These authors also reported that 
EGFRvIII-negative neurosphere cells are more resistant to temozolomide than EGFRvIII-
positive cells suggesting that expression of EGFRvIII rather acts as a sensitizer to alkylating 
drugs. Notable, very high concentrations of TMZ were used for these in vitro studies which 
precludes translation into a clinical setting. Indeed, these findings are at odds with other 
reports. A study by Shinojima and colleagues revealed an association between EGFRvIII 
expression and poor overall survival in glioblastoma patients 43. Ultimately, a comprehensive 
analysis of more than 180 glioblastoma patients demonstrated that the clinical course of 
EGFRvIII-expressing glioblastomas is not significantly different from that of patients 
harbouring EGFRvIII-negative tumors. However, long-term survival, defined by overall 
survival of more than 3 years, was virtually absent in patients with EGFRvIII-positive 
glioblastoma 44.  
Expression of EGFRvIII also defines a subgroup of tumor cells within a glioblastoma with 
stem cell characteristics 45. It was reported that EGFRvIII is coexpressed with the putative 
stem cell marker CD133 and that these cells are characterized by the highest degree of self-
renewal as well as a pronounced tumorigenicity in vivo. On the cellular level, there is a close 
oncogenic signalling relationship between wild-type EGFR and EGFRvIII which drives 
glioblastoma progression 46. Furthermore, a minority of cells within a glioblastoma expressing 
the EGFRvIII mutant may be sufficient to promote tumor growth by inducing the expression 
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of several cytokines such as interleukin (IL)-6 and leukemia inhibitory factor (LIF). 
Subsequently, these cytokines act in a paracrine manner on EGFRvIII-negative cells in the 
neighbourhood by accelerating their proliferation 47. Accordingly, the specific targeting of 
EGFRvIII may have an impact on tumor growth beyond the population of EGFRvIII-positive 
cells. Proteomic analyses revealed that the expression of EGFRvIII results in the activation of 
different downstream pathways compared to gliomas that are EGFRvIII-deficient 48. In this 
regard, preclinical data suggest a synergistic activity when EGFRvIII inhibition is combined 
with targeting of an additional pathway such as c-MET signalling or the urokinase-type 
plasminogen activator (uPAR) receptor pathway 49,50. It was also reported that resistance to 
anti-EGFR strategies is associated with increased expression of EGFRvIII and an activation 
of the PI3K pathway. The latter is accompanied by an induction of the expression of the 
regulatory 110-kDa delta subunit of PI3K (p110δ). Preclinical findings suggest that insulin-
like growth factor receptor (IGFR)-I signaling via PI3K and the presence of major vault 
proteins (MVP) which stabilize EGFR/PI3K signalling also contribute to resistance to anti-
EGFR therapy in glioma cells 51,52. Silencing of EGFRvIII resulted in a sensitization to the 
EGFR inhibitor erlotinib. Similary, targeting PI3K or the p110δ subunit also restored erlotinib 
sensitivity 53. Considering these findings, the selective interfering with EGFRvIII signalling 
may help to overcome the treatment resistance of glioblastomas.  
 
Immunotherapy: escape from vaccination against EGFRvIII 
 
Since EGFRvIII is exclusively expressed on tumor cells, it represents an appealing target for 
therapeutic interventions. In contrast to wild-type EGFR which has been used as a point of 
attack for pharmacological inhibitors or antibodies, EGFRvIII has gained additional interest 
as target structure for active immunotherapy, that is, vaccination which aims at overcoming 
the immune evasion of glioma cells 54. Currently, a peptide-based vaccine (CDX-110, also 
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known as rindopepimut) is in late stage clinical development and assessed in combination 
with standard temozolomide-based chemoradiation in patients with newly diagnosed 
glioblastoma with proven expression of EGFRvIII (ACT IV, NCT01480479) as well as in a 
phase II study in patients with relapsed EGFRvIII-positive glioblastoma (ReACT, 
NCT01498328). This vaccine has already shown promising results in smaller trials and 
prolonged survival compared to matched historical controls. However, it was also reported 
that the expression of EGFRvIII is lost upon vaccination with rindopepimut when tissue 
specimens from recurrent tumors were compared to the tumor tissue at initial diagnosis 55. On 
the one hand, this may indicate the activity of the vaccine and the removal of tumor cells 
expressing the target antigen by the immune system. On the other hand, it also suggests 
immune evasion by the tumor due to loss of the target structure. This process, also known as 
“cancer immunoediting” precludes durable immune responses against glioma cells unless 
further tumor antigens are recognized by the effector mechanisms of the immune system 56. 
Currently, various strategies aiming at boosting the immune system against cancer are 
investigated in clinical trials. Immune checkpoint inhibitors targeting programmed cell death 
(PD)-1 or cytotoxic T lymphocyte antigen (CTLA)-4 as well as drugs which may help to 
overcome the immunosuppressive environment surrounding glioma, e.g. by suppressing 
transforming growth factor (TGF)-β signalling, may allow for more powerful immune 
responses against gliomas. However, whether the combination of any of these novel 
approaches with a vaccine against EGFRvIII prevents escape from vaccination alone and 
results in sustained clinical benefit, must be determined within clinical trials.  
 
Outlook 
 
TCGA has reconfirmed the EGFR gene as a principal target of mutation in glioblastoma, but 
also illustrated the variability of alterations. The history of negative trials with EGFR-targeted 
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agents teaches us that any future effort at exploiting this target for therapy must be based on a 
molecularly defined patient enrichment including at least EGFR status, but potentially also 
changes in associated pathways (Fig. 1). Advances with the use of anti-EGFR treatments will 
require stratification based on the presence of EGFR overexpression or amplification as well 
as the presence of the EGFRvIII mutation. Patients with tumors harbouring any of these 
alterations may be most likely to benefit from EGFR-targeted therapies. While the fate of the 
immunotherapeutic efforts targeting EGFRvIII will depend on the outcome of the currently 
ongoing trials, the availability of antibody-drug conjugates as well as the selection of drug 
combinations selected upon individual tumor tissue examination may pave the road for more 
successful therapies.  
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Figure legend 
 
Figure 1. Treatment approach to glioblastoma based on EGFR-stratification. 
Abbreviations: CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; 
EGFRvIII, EGFR variant III; mTOR, mechanistic target of rapamycin; PDGFR-β, platelet-
derived growth factor receptor β. ClinicalTrials.gov identifier: ACT IV (NCT01480479), 
ReACT (NCT01498328) 
 
